Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
... (mecasermin rinfabate) in patients with myotonic muscular
dystrophy ("MMD"). The randomized, double-blind, ... the Company intends to apply for a grant from the muscular
Dystrophy Association ("MDA") to facilitate an ... RBC Capital Markets."
About Myotonic muscular
PTC Therapeutics Receives $2.6 Million in Government Grants
... in nonsense mutation Duchenne and Becker muscular
(Logo: ... FDA's Office of Orphan Products Development, the muscular
Dystrophy Association, the Parent Project muscular
Dystrophy, and the National Center for Research ...
PTC Therapeutics and Spinal Muscular Atrophy Foundation Announce $8.5 Million Small Molecule Development Collaboration
... advance novel platform for treatment of Spinal muscular
SOUTH PLAINFIELD, N.J. and NEW ... -- PTC Therapeutics, Inc. (PTC) and the Spinal muscular
Atrophy (SMA) Foundation today announced the ... site at www.ptcbio.com .
About Spinal muscular
Assay Designs(TM), Inc. and the Spinal Muscular Atrophy Foundation Announce Collaboration To Accelerate the Discovery of New Therapeutics for Spinal Muscular Atrophy (SMA)
... drug discovery and development
efforts for spinal muscular
atrophy (SMA), the leading genetic cause ... the
spinal cord, the disease leads to increasing muscular
weakness and atrophy.
It is estimated that ... sit up and
Founded in 2003, the Spinal muscular
Atrophy Foundation is a nonprofit
Repligen Receives Research Grants to Support Friedreich's Ataxia Development Program
... "We are very pleased to receive support from the muscular
Association, the Friedreich's Ataxia ... Huntington's disease and spinal muscular
atrophy. The MDA grant
will partially support the ... or cure for
About the muscular
PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
... of PTC124 for
nonsense-mutation Duchenne/Becker muscular
dystrophy ongoing and are
planning ... has also been supported by grants from, the muscular
Association, Parent Project muscular
Dystrophy, FDA's Office of Orphan
Genzyme Corporation and PTC Therapeutics Announce Collaboration on Small Molecule for Genetic Diseases
... and in
nonsense-mutation-mediated Duchenne muscular
dystrophy, PTC124 has
demonstrated the ability to ... Muscular
Dystrophy Association, Parent Project muscular
Dystrophy, FDA's Office of
Orphan Products ... Center for Research Resources.
About Duchenne muscular
Palladian Muscular Skeletal Health (formerly Prism Health Networks) to Promote Collaborative, Expanded Practice Model at Major Insurance Conference in June
Skeletal Managed Care Organization Takes ... SENECA, N.Y., June 11 /PRNewswire/ -- Palladian muscular
Health (formerly Prism Health Networks) ... Palladian as the
imminent leader in innovative muscular
skeletal healthcare solutions," said
PTC124 Featured at Third Annual Congress of Myology
... Francaise contre les
Myopathies (French muscular
Dystrophy Association) and focuses on research,
therapies and clinical trials for various forms of muscular
(Logo: ... )
PTC124 is being studied in Duchenne muscular
dystrophy (DMD), a
progressive muscle disorder in ...
AMT's Cooperative Research and Development Agreement With NIH to Boost Production Capacity
developed for treating Duchenne muscular
Dystrophy (DMD) by Robert Kotin,
Ph.D., and ... is also important for
treatment of Duchenne muscular
Dystrophy (DMD) for which AMT has just
closed an ... local)
expression of therapeutic genes. Duchenne muscular
Dystrophy is such a
disease, and together with La ...
AMT Accesses Technology for Treatment of Duchenne Muscular Dystrophy
administration of the product.
dystrophy, caused by mutations in the dystrophin ... will result
in long-term treatment of Duchenne muscular
Formalizing relationship with ...
Families of Spinal Muscular Atrophy; University of California, Irvine Stem Cell Scientist; and California Stem Cell Announce Collaboration for Safety Studies for Stem Cell Therapy in Spinal Muscular Atrophy
... 19 /PRNewswire-USNewswire/ -- Families of
Atrophy (FSMA); a stem cell scientist at ... Lateral Sclerosis
(ALS) in addition to Spinal muscular
About Families of Spinal muscular
Families of SMA is dedicated to ...
Insmed Awarded $2.1 Million by Muscular Dystrophy Association
... has been awarded a grant of $2,087,325 from
Dystrophy Association (MDA). The grant is ... 3 enabling trial in patients with Myotonic muscular
Insmed, a development stage ... symptoms
commonly associated with Myotonic muscular
Dystrophy. Furthermore, patients
undergoing a ...
European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera
... SNT-MC17's second potential indication, Duchenne muscular
(DMD). About Friedreich's Ataxia ... treatment of Friedreich's Ataxia (FRDA), Duchenne muscular
(DMD) and Leber's Hereditary Optic ... comprises SNT-317 (INN: omigapil) in
Dystrophies (CMD), a compound in-licensed ...
Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
Completed the Phase 2 trial of IPLEX(TM) in Myotonic muscular
Dystrophy (MMD), and expect preliminary data in the second quarter of ... patients with ALS in Italy and the grant receipt of $1.0 million from the muscular
Dystrophy Association supporting the IPLEX(TM) MMD trial. This was ...
Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
... patients with ALS in Italy and the
grant receipt of $1.0 million from the muscular
supporting the IPLEX(TM) Phase 2 Myotonic muscular
Dystrophy ("MMD") trial.
The net loss for the third quarter of 2008 was ...
Insmed CEO to Present at Drug Discovery & Development Conference
... Discuss Company's IPLEX(TM) Program in Myotonic muscular
RICHMOND, Va., July 25 /PRNewswire-FirstCall/ -- Insmed Inc. ... Insmed's progress
with its Phase II trial for IPLEX(TM) in Myotonic muscular
trial, which has seen strong patient and physician ...
A New President at the Head of the Genethon Laboratory
... a new president to head the laboratory created in 1990 by the AFM
Dystrophy Association). Thus Yves Champey succeeds Bernard
Barataud, who ... exist with public research organisations."
President of the AFM (French muscular
Dystrophy Association) from 1981
to 2001, Bernard Barataud is the father ...
Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
... study of IPLEX(TM) in six patients with myotonic muscular
dystrophy ("MMD") that met the primary study endpoints of being ... in 60 patients with MMD; -- Awarded a grant of $2.1 million from the muscular
Dystrophy Association ("MDA"), which is expected to cover a ...
PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
... of PTC124 in nonsense-mutation-mediated cystic fibrosis (CF) and
dystrophy (DMD). It is estimated that 10% of the cases of CF and 13% of ... European Commission. PTC124's
development is supported by grants from the muscular
(MDA), Cystic Fibrosis Foundation Therapeutics, Inc. ...
Repligen Reports First Quarter Fiscal Year 2010 Financial Results
... revenue of $2,588,000, consisting primarily of royalty payments from Bristol-Myers Squibb on the U.S. sales of Orencia(R) and grant revenue from the muscular
Operating expenses for the first quarter of fiscal year 2010 were $6,489,000 compared to $5,702,000 for the same period ...
Muscular protein bond -- strongest yet found in nature
... events from non-specific interactions as well as from multi-molecule events.
Their measurements confirm that in the direction that corresponds to muscular
contraction and relaxation, the titin-telethonin complex is the strongest protein bond found so far in nature. When force was applied in different ...
iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming
... Highland Capital Partners, MPM Capital and FinTech Global Capital. The initial focus of the company is in neurodegeneration, particularly spinal muscular
atrophy (SMA), amyotrophic lateral sclerosis (ALS) and Parkinson's disease as well as in cardiovascular disease, where iPierian has a collaboration ...
Bay Area Youth to Represent ALS Patients at Giants' and Angels' Baseball Games on July 4th
... League Baseball's "4ALS Awareness" campaign. MLB is working with four leading organizations -- The ALS Association, ALS TDI, Augie's Quest (the muscular
Dystrophy Association's ALS research initiative) and Project A.L.S. -- whose primary goal is to find a cure for ALS. The initiative will culminate on ...
Ten Top Latin American Scientists Named 2009 Pew Fellows in the Biomedical Sciences
... Eisner, Ph.D.
Laboratory of Gyorgy Hajnoczky, M.D., Ph.D.
Thomas Jefferson University
Mitochondria and muscular
Ramon A. Jorquera, Ph.D.
Laboratory of J. Troy Littleton, M.D., Ph.D.
iZumi Bio Appoints Dr. Corey Goodman to Board of Directors and Scientific Advisory Board
... extensive knowledge and leadership in neurology to help advance our proprietary neurodegenerative programs in amyotrophic lateral sclerosis, spinal muscular
atrophy and Parkinson's disease," said John P. Walker, chief executive officer of iZumi. "Over the next few months, we intend to build a ...
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
... $14,833,000, comprised primarily of royalty payments from Bristol-Myers Squibb on the U.S. sales of Orencia(R) (abatacept) and grant revenue from the muscular
Operating expenses for fiscal year 2009 were $25,482,000 compared to $23,574,000, exclusive of the net gain of ...
MEDomics Announces MitoDx(TM), the First NextGen Mitochondrial Genome Diagnostic Test
... from mutations in mitochondrial DNA is now thought to be common in both adults and children. In childhood, mitochondrial disease is more common than muscular
dystrophy or cancer. Most mitochondrial disease may go undiagnosed because a primary care physician does not suspect the disease or because the ...
Insmed Announces First Quarter 2009 Financial Results
... $125 million.
Continue to expect preliminary Phase 2 data in Myotonic muscular
Dystrophy (MMD) in the second quarter of 2009;
The FDA announced that it would allow Insmed to provide access to IPLEX(TM) for ...
iZumi Bio Appoints Dr. Berta Strulovici as Chief Technology Officer and Dr. Dushyant Pathak as Vice President of Business Development
... by Kleiner Perkins Caufield and Byers and Highland Capital Partners. The initial focus of the company is in neurodegeneration, particularly spinal muscular
atrophy (SMA), amyotrophic lateral sclerosis (ALS) and Parkinson's disease as well as in cardiovascular disease, where iZumi has a collaboration with ...
BioMarin Announces First Quarter 2009 Financial Results
... a decision on the future of the 6R-BH4 cardiovascular program by the third quarter of 2009.
BMN-195 - Utrophin upregulator for Duchenne muscular
Dystrophy: BioMarin is completing reformulation work and toxicology studies and expects to initiate a Phase I trial by the first quarter of 2010. ...
Repair Stem Cell Institute Warns About Real Cost of Embryonic Stem Cell Research
... "Patients stricken with disabling diseases such as congestive heart failure, diabetes, multiple sclerosis, spinal cord injuries, cerebral palsy, muscular
dystrophy, ataxia, autism, COPD, emphysema, Crohn's, and optic nerve disorders, among 100+ other conditions, are receiving successful stem cell ...
Amsterdam Molecular Therapeutics Reports Full Year Results 2008
... resigned for personal reasons
- Start of clinical multicenter Hemophilia B trial in 2009
- Start development of treatments for Duchenne muscular
- Scale up of unique and proprietary production platform to fully support
worldwide commercial ...
Seminar Will Bring ALS Researchers to Patient Groups
... of life issues. The speakers will also describe the impact a three-year, $18 million funding and scientific collaboration between ALS TDI and the muscular
Dystrophy Association's Augie's Quest initiative has had on the pace of research, as well as the recently announced 4ALS Awareness charitable ...
Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
... $2,724,000, comprised primarily of royalty payments from Bristol-Myers Squibb on the U.S. sales of Orencia(R) (abatacept) and grant revenue from the muscular
Operating expenses for the third quarter of fiscal year 2009 were $6,556,000 compared to $5,663,000 for the same period ...
Update: Georgia and North Carolina Teens Honored for Research in Biochemistry and Genetics in Nation's Premier High School Science Competition
... with his hypothesis in each case,
ultimately creating a shift in the way we think about controlling cell death
for diseases such as Parkinson's, muscular
Dystrophy and Cancer."
Mr. Meixiong is the Team Captain of his school's Science Bowl and the
Olympiad Team and also manages his school's swim ...
Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants
... further evidence of the effectiveness of IPLEX(TM) in
potentially treating some of the most under-served therapeutic populations,
including Myotonic muscular
Dystrophy and Amyotrophic Lateral Sclerosis."
Clinical Study Results
Low levels of IGF-I are known to contribute to the pathogenesis of ROP.
Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntington's Disease Model
... disease, Repligen is evaluating this family of
compounds for activity in preclinical models of other neurodegenerative
diseases including spinal muscular
About The Scripps Research Institute
The Scripps Research Institute is one of the world's largest
independent, non-profit biomedical ...
Amsterdam Molecular Therapeutics Reports Half Year Results 2008
... for Hyperlipoproteinemia type I - European patent for treatment of Non-Alcoholic Steatotic Hepatitis - License for treatment of Duchenne muscular
Dystrophy from La Sapienza University, Rome, Italy - License for prevention of immune response against treatment of Hemophilia B from 'TIGET", San ...
Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
... financial advisor to evaluate and focus the Company's strategic initiatives. -- IPLEX(TM) -- The Phase 2 trial of IPLEX(TM) in Myotonic muscular
Dystrophy ("MMD"), which was initiated in December 2007, has seen a strong patient and physician interest and is now fully enrolled; ...